Drug intelligence / Profile preview

SP-26

Development stage: Preclinical
Lead developer: Silo Pharma
Modality: Small Molecules
Administration: Subcutaneous, Implant

Overview

SP-26 is a developmental-stage therapeutic candidate consisting of a dissolvable subcutaneous polymer implant for the controlled delivery of ketamine hydrochloride. Developed by Silo Pharma, it is primarily targeted for the treatment of fibromyalgia and chronic pain. The implant is designed to provide sustained, systemic release of ketamine, potentially offering a non-opioid alternative for pain management with improved patient compliance and a reduced side-effect profile compared to intermittent dosing. Silo Pharma intends to pursue the FDA's 505(b)(2) regulatory pathway for its clinical development, leveraging existing safety and efficacy data for ketamine.

Other names: ketamine hydrochloride implant

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on SP-26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-26.

Explore the full profile